Hematopoietic expression of oncogenic BRAF promotes aberrant growth of monocyte-lineage cells resistant to PLX4720

Molecular Cancer Research

Volumn 11, Issue 12, 2013, Pages 1530-1541

  Kamata, Tamihiro ^a,b   Dankort, David ^a,c   Kang, Jing ^a   Giblett, Susan ^b   Pritchard, Catrin A ^b   McMahon, Martin ^a   Leavitt, Andrew D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CYTOKINE; PHOSPHATIDYLINOSITOL 3 KINASE;

ANEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE MARROW; BONE MARROW CELL; BONE MARROW TRANSPLANTATION; CELL LINEAGE; COLONY FORMATION; CONTROLLED STUDY; ENZYME ACTIVATION; ERYTHROPOIESIS; FLOW CYTOMETRY; GENOTYPE; HEMATOPOIETIC TISSUE; IN VITRO STUDY; IN VIVO STUDY; LEUKOCYTOSIS; MACROPHAGE; MONOCYTE; MONOCYTOSIS; MOUSE; MYELOPOIESIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN; THROMBOCYTOPENIA;

ANIMALS; BENZAMIDES; BONE MARROW TRANSPLANTATION; CELL LINE, TUMOR; CELL PROLIFERATION; CELLS, CULTURED; CYTOKINES; DIPHENYLAMINE; DRUG RESISTANCE, NEOPLASM; ERYTHROPOIESIS; FURANS; GENE EXPRESSION REGULATION, NEOPLASTIC; HEMATOLOGIC NEOPLASMS; HUMANS; INDOLES; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MONOCYTE-MACROPHAGE PRECURSOR CELLS; MONOCYTES; MYELOPOIESIS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; PYRIDINES; PYRIMIDINES; RAF KINASES; SIGNAL TRANSDUCTION; SULFONAMIDES;

EID: 84891348926     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-13-0294     Document Type: Article

References (48)

1. Kamata T, Pritchard C. Mechanisms of aneuploidy induction by RAS and RAF oncogenes. Am J Cancer Res 2011;1:955-71.
2. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of theBRAF gene in human cancer. Nature 2002;417:949-54.
3. Gustafsson B, Angelini S, Sander B, Christensson B, Hemminki K, Kumar R. Mutations in the BRAF and N-ras genes in childhood acute lymphoblastic leukaemia. Leukemia 2005;19:310-2.
4. Lee JW, Soung YH, Park WS, Kim SY, Nam SW, Min WS, et al. BRAF mutations in acute leukemias. Leukemia 2004;18:170-2.
5. Christiansen DH, Andersen MK, Desta F, Pedersen-Bjergaard J. Mutations of genes in the receptor tyrosine kinase (RTK)/RAS-BRAF signal transduction pathway in therapy-related myelodysplasia and acute myeloid leukemia. Leukemia 2005;19:2232-40.
6. Lee JW, Yoo NJ, Soung YH, Kim HS, Park WS, Kim SY, et al. BRAF mutations in non-Hodgkin's lymphoma. Br J Cancer 2003;89:1958-60.
7. Chapman MA, Lawrence MS, Keats JJ, Cibulskis K, Sougnez C, Schinzel AC, et al. Initial genome sequencing and analysis of multiple myeloma. Nature 2011;471:467-72.
8. Tiacci E, Trifonov V, Schiavoni G, Holmes A, Kern W, Martelli MP, et al. BRAF mutations in hairy-cell leukemia. N Engl J Med 2011;364: 2305-15.
9. Badalian-Very G, Vergilio JA, Degar BA, MacConaill LE, Brandner B, Calicchio ML, et al. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood 2010;116:1919-23.
10. Haroche J, Charlotte F, Arnaud L, von Deimling A,Hélias-Rodzewicz Z, Hervier B, et al. High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. Blood 2012;120:2700-3
11. Mercer KE, Pritchard CA. Raf proteins and cancer: B-Raf is identified as a mutational target. Biochim Biophys Acta 2003;1653:25-40.
12. Garnett MJ, Marais R. Guilty as charged: B-RAF is a human oncogene. Cancer Cell 2004;6:313-9.
13. Dankort D, Filenova E, Collado M, Serrano M, Jones K, McMahon M. A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors. Genes Dev 2007;21: 379-84.
14. Dankort D, Curley DP, Cartlidge RA, Nelson B, Karnezis AN, Damsky WE Jr, et al. BrafV600E cooperates with Pten loss to induce metastatic melanoma. Nat Genet 2009;41:544-52.
15. Kamata T, Kang J, Lee TH, Wojnowski L, Pritchard CA, Leavitt AD. A critical function for B-Raf at multiple stages of myelopoiesis. Blood 2005;106:833-40.
16. Zhang J, Lodish HF. Constitutive activation of the MEK/ERK pathway mediates all effects of oncogenicH-ras expression in primary erythroid progenitors. Blood 2004;104:1679-87.
17. Mercer K, Giblett S, Green S, Lloyd D, DaRocha Dias S, Plumb M, et al. Expression of endogenous oncogenic V600EB-raf induces proliferation and developmental defects in mice and transformation of primary fibroblasts. Cancer Res 2005;65:11493-500.
18. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAFV600E mutation. N Engl J Med 2011;364:2507-16.
19. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicenter, open-label, phase 3 randomised controlled trial. Lancet 2012;380: 358-65.
20. Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012;367:107-14.
21. Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, Zecchin D, et al. Unresponsiveness of colon cancer to BRAFV600E inhibition through feedback activation of EGFR. Nature 2012;483:100-3.
22. Girotti MR, Pedersen M, Sanchez-Laorden B, Viros A, Turajlic S, Niculescu-Duvaz D, et al. Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma. Cancer Discov 2013;3:158-67.
23. Corcoran RB, Ebi H, Turke AB, Coffee EM, Nishino M, Cogdill AP, et al. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov 2012;2:227-35.
24. Dietrich S, Glimm H, Andrulis M, von Kalle C, Ho AD, Zenz T. BRAF inhibition in refractory hairy-cell leukemia. N Engl J Med 2012;366: 2038-40.
25. Haroche J, Cohen-Aubart F, Emile JF, Arnaud L, Maksud P, Charlotte F, et al. Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAFV600E mutation. Blood 2013;121:1495-500.
26. Kuhn R, Schwenk F, Aguet M, Rajewsky K. Inducible gene targeting in mice. Science 1995;269:1427-9.
27. Goldman JP, Blundell MP, Lopes L, Kinnon C, Di Santo JP, Thrasher AJ. Enhanced human cell engraftment in mice deficient in RAG2 and the common cytokine receptor gamma chain. Br J Haematol 1998; 103:335-42.
28. Walter R, Schoedon G, Bachli E, Betts DR, Hossle JP, Calandra T, et al. Establishment and characterization of an arsenic-sensitive monoblastic leukaemia cell line (SigM5). Br J Haematol 2000;109:396-404
29. Kamata T, Pritchard CA, Leavitt AD. Raf-1 is not required for megakaryocytopoiesis and TPO-induced ERK phosphorylation. Blood 2004;103:2568-70.
30. Kamata T, Hussain J, Giblett S, Hayward R, Marais R, Pritchard C. BRAF inactivation drives aneuploidy by deregulating CRAF. Cancer Res 2010;70:8475-86.
31. Socolovsky M, Nam H-S, Fleming MD, Haase VH, Brugnara C, Lodish HF. Ineffective erythropoiesis in Stat5a(-/-)5b(-/-) mice due to decreased survival of early erythroblasts. Blood 2001;98:3261-73.
32. Pileri SA, Grogan TM, Harris NL, Banks P, Campo E, Chan JK, et al. Tumours of histiocytes and accessory dendritic cells: an immunohistochemical approach to classification from the International Lymphoma Study Group based on 61 cases. Histopathology 2002;41:1-29.
33. Wilson TR, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E, et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 2012;487:505-9.
34. Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian ZR, Du J, et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 2012;487:500-4.
35. Braun BS, Shannon K. Targeting Ras in myeloid leukemias. Clin Cancer Res 2008;14:2249-52.
36. Chan IT, Kutok JL, Williams IR, Cohen S, Kelly L, Shigematsu H, et al. Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease. J Clin Invest 2004;113: 528-38.
37. Braun BS, Tuveson DA, Kong N, Le DT, Kogan SC, Rozmus J, et al. Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder. Proc Natl Acad Sci USA 2004;101:597-602.
38. Wang J, Liu Y, Li Z, Du J, Ryu MJ, Taylor PR, et al. Endogenous oncogenic Nras mutation promotes aberrant GM-CSF signaling in granulocytic/monocytic precursors in a murine model of chronic myelomonocytic leukemia. Blood 2010;116:5991-6002.
39. Lyubynska N, Gorman MF, Lauchle JO, Hong WX, Akutagawa JK, Shannon K, et al. AMEK inhibitor abrogates myeloproliferative disease in Kras mutant mice. Sci Transl Med 2011;3:76ra27.
40. Sabnis AJ, Cheung LS, Dail M, Kang HC, Santaguida M, Hermiston ML, et al. Oncogenic Kras initiates leukemia in hematopoietic stem cells. PLoS Biol 2009;7:e59.
41. Van Meter ME, Díaz-Flores E, Archard JA, Passegué E, Irish JM, Kotecha N, et al. K-RasG12D expression induces hyperproliferation and aberrant signaling in primary hematopoietic stem/progenitor cells. Blood 2007;109:3945-52.
42. Zhang J,Wang J, Liu Y, Sidik H, Young KH, Lodish HF, et al. Oncogenic Kras-induced leukemogeneis: hematopoietic stem cells as the initial target and lineage-specific progenitors as the potential targets for final leukemic transformation. Blood 2009;113:1304-14.
43. Hsu CL, Kikuchi K, Kondo M. Activation of mitogen-activated protein kinase kinase (MEK)/extracellular signal regulated kinase (ERK) signaling pathway is involved in myeloid lineage commitment. Blood 2007;110:1420-8.
44. Blalock WL, Navolanic PM, Steelman LS, Shelton JG, Moye PW, Lee JT, et al. Requirement for the PI3K/Akt pathway in MEK1-mediated growth and prevention of apoptosis: identification of an Achilles heel in leukemia. Leukemia 2003;17:1058-67.
45. Shelton JG, Steelman LS, Lee JT, Knapp SL, Blalock WL, Moye PW, et al. Effects of the RAF/MEK/ERK and PI3K/AKT signal transduction pathways on the abrogation of cytokine-dependence and prevention of apoptosis in hematopoietic cells. Oncogene 2003;22:2478-92.
46. Heidorn SJ, Milagre C, Whittaker S, Nourry A, Niculescu-Duvas I, Dhomen N, et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 2010;140:209-21.
47. Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 2010;464:427-30.
48. Su F, Viros A, Milagre C, Trunzer K, Bollag G, Spleiss O, et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 2012;366:207-15.